Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.

Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O.

Cancer. 2019 Apr 1;125(7):1113-1123. doi: 10.1002/cncr.31892. Epub 2019 Jan 28.

PMID:
30690710
2.

Commentary on Folkman: "Tumor Angiogenesis Factor".

Bagley RG.

Cancer Res. 2016 Apr 1;76(7):1673-4. doi: 10.1158/0008-5472.CAN-16-0675. No abstract available.

3.

JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.

Debeurme F, Lacout C, Moratal C, Bagley RG, Vainchenker W, Adrian F, Villeval JL.

J Cell Mol Med. 2015 Nov;19(11):2564-74. doi: 10.1111/jcmm.12608. Epub 2015 Jul 14.

4.

Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer.

Chiron M, Bagley RG, Pollard J, Mankoo PK, Henry C, Vincent L, Geslin C, Baltes N, Bergstrom DA.

Mol Cancer Ther. 2014 Jun;13(6):1636-44. doi: 10.1158/1535-7163.MCT-13-0753. Epub 2014 Mar 31.

5.

Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia.

Nguyen TH, Weber W, Havari E, Connors T, Bagley RG, McLaren R, Nambiar PR, Madden SL, Teicher BA, Roberts B, Kaplan J, Shankara S.

Int J Oncol. 2012 Sep;41(3):829-38. doi: 10.3892/ijo.2012.1513. Epub 2012 Jun 12.

6.

Human choriocarcinomas: placental growth factor-dependent preclinical tumor models.

Bagley RG, Ren Y, Kurtzberg L, Weber W, Bangari D, Brondyk W, Teicher BA.

Int J Oncol. 2012 Feb;40(2):479-86. doi: 10.3892/ijo.2011.1257. Epub 2011 Nov 10.

PMID:
22075622
7.

Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy.

Bagley RG, Rouleau C, Weber W, Mehraein K, Smale R, Curiel M, Callahan M, Roy A, Boutin P, St Martin T, Nacht M, Teicher BA.

Microvasc Res. 2011 Nov;82(3):253-62. doi: 10.1016/j.mvr.2011.09.004. Epub 2011 Sep 17.

PMID:
21958527
8.

Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling.

Rouleau C, Smale R, Fu YS, Hui G, Wang F, Hutto E, Fogle R, Jones CM, Krumbholz R, Roth S, Curiel M, Ren Y, Bagley RG, Wallar G, Miller G, Schmid S, Horten B, Teicher BA.

Int J Oncol. 2011 Jul;39(1):73-89. doi: 10.3892/ijo.2011.1020. Epub 2011 Apr 29.

PMID:
21537839
9.

Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells.

Bagley RG, Kurtzberg L, Rouleau C, Yao M, Teicher BA.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1537-46. doi: 10.1007/s00280-011-1658-0. Epub 2011 Apr 28.

PMID:
21526352
10.

Characteristics of human Ewing/PNET sarcoma models.

Teicher BA, Bagley RG, Rouleau C, Kruger A, Ren Y, Kurtzberg L.

Ann Saudi Med. 2011 Mar-Apr;31(2):174-82. doi: 10.4103/0256-4947.78206. Review.

11.

Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.

Kurtzberg LS, Roth S, Krumbholz R, Crawford J, Bormann C, Dunham S, Yao M, Rouleau C, Bagley RG, Yu XJ, Wang F, Schmid SM, Lavoie EJ, Teicher BA.

Clin Cancer Res. 2011 May 1;17(9):2777-87. doi: 10.1158/1078-0432.CCR-10-0542. Epub 2011 Mar 17.

12.

Placental growth factor upregulation is a host response to antiangiogenic therapy.

Bagley RG, Ren Y, Weber W, Yao M, Kurtzberg L, Pinckney J, Bangari D, Nguyen C, Brondyk W, Kaplan J, Teicher BA.

Clin Cancer Res. 2011 Mar 1;17(5):976-88. doi: 10.1158/1078-0432.CCR-10-2687. Epub 2011 Feb 22.

13.

sFLT01: a novel fusion protein with antiangiogenic activity.

Bagley RG, Kurtzberg L, Weber W, Nguyen TH, Roth S, Krumbholz R, Yao M, Richards B, Zhang M, Pechan P, Schmid S, Scaria A, Kaplan J, Teicher BA.

Mol Cancer Ther. 2011 Mar;10(3):404-15. doi: 10.1158/1535-7163.MCT-10-0813. Epub 2011 Jan 20.

14.

Endosialin: from vascular target to biomarker for human sarcomas.

Bagley RG.

Biomark Med. 2009 Oct;3(5):589-604. doi: 10.2217/bmm.09.54.

PMID:
20477527
15.

Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.

Bagley RG, Roth S, Kurtzberg LS, Rouleau C, Yao M, Crawford J, Krumbholz R, Lovett D, Schmid S, Teicher BA.

Int J Oncol. 2009 May;34(5):1329-40.

PMID:
19360345
16.

Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.

Kurtzberg LS, Roth SD, Bagley RG, Rouleau C, Yao M, Crawford JL, Krumbholz RD, Schmid SM, Teicher BA.

Cancer Chemother Pharmacol. 2009 Oct;64(5):1029-38. doi: 10.1007/s00280-009-0959-z. Epub 2009 Mar 10.

PMID:
19277662
17.

Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers.

Bagley RG, Weber W, Rouleau C, Yao M, Honma N, Kataoka S, Ishida I, Roberts BL, Teicher BA.

Int J Oncol. 2009 Mar;34(3):619-27.

PMID:
19212666
18.

Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.

Kurtzberg LS, Battle T, Rouleau C, Bagley RG, Agata N, Yao M, Schmid S, Roth S, Crawford J, Krumbholz R, Ewesuedo R, Yu XJ, Wang F, Lavoie EJ, Teicher BA.

Mol Cancer Ther. 2008 Oct;7(10):3212-22. doi: 10.1158/1535-7163.MCT-08-0568.

19.

Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization.

Bagley RG, Honma N, Weber W, Boutin P, Rouleau C, Shankara S, Kataoka S, Ishida I, Roberts BL, Teicher BA.

Microvasc Res. 2008 Nov;76(3):180-8. doi: 10.1016/j.mvr.2008.07.008. Epub 2008 Aug 8.

PMID:
18761022
20.

Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248.

Bagley RG, Rouleau C, St Martin T, Boutin P, Weber W, Ruzek M, Honma N, Nacht M, Shankara S, Kataoka S, Ishida I, Roberts BL, Teicher BA.

Mol Cancer Ther. 2008 Aug;7(8):2536-46. doi: 10.1158/1535-7163.MCT-08-0050.

21.

Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy.

Bagley RG, Rouleau C, Morgenbesser SD, Weber W, Cook BP, Shankara S, Madden SL, Teicher BA.

Microvasc Res. 2006 May;71(3):163-74. Epub 2006 Apr 19.

PMID:
16624341
22.

Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy.

Bagley RG, Weber W, Rouleau C, Teicher BA.

Cancer Res. 2005 Nov 1;65(21):9741-50.

23.

Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells.

Bagley RG, Walter-Yohrling J, Cao X, Weber W, Simons B, Cook BP, Chartrand SD, Wang C, Madden SL, Teicher BA.

Cancer Res. 2003 Sep 15;63(18):5866-73.

24.

Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes.

Yew NS, Wang KX, Przybylska M, Bagley RG, Stedman M, Marshall J, Scheule RK, Cheng SH.

Hum Gene Ther. 1999 Jan 20;10(2):223-34.

PMID:
10022547
25.

Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung.

Scheule RK, St George JA, Bagley RG, Marshall J, Kaplan JM, Akita GY, Wang KX, Lee ER, Harris DJ, Jiang C, Yew NS, Smith AE, Cheng SH.

Hum Gene Ther. 1997 Apr 10;8(6):689-707.

PMID:
9113509
26.

Delivery of purified, functional CFTR to epithelial cells in vitro using influenza hemagglutinin.

Scheule RK, Bagley RG, Erickson AL, Wang KX, Fang SL, Vaccaro C, O'Riordan CR, Cheng SH, Smith AE.

Am J Respir Cell Mol Biol. 1995 Sep;13(3):330-43.

PMID:
7544596
27.

Framework multipoint map of the long arm of human chromosome 4 and telomeric localization of the gene for FSHD.

Weiffenbach B, Bagley RG, Falls K, Dubois J, Hyser C, Storvick D, Schultz P, Mendell JR, Milner EC, Jacobsen SJ, et al.

Mamm Genome. 1992;3(3):143-50.

PMID:
1352159

Supplemental Content

Loading ...
Support Center